These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16716107)

  • 1. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus.
    Zhi Y; Figueredo J; Kobinger GP; Hagan H; Calcedo R; Miller JR; Gao G; Wilson JM
    Hum Gene Ther; 2006 May; 17(5):500-6. PubMed ID: 16716107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
    Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
    Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.
    Xu K; Song Y; Dai L; Zhang Y; Lu X; Xie Y; Zhang H; Cheng T; Wang Q; Huang Q; Bi Y; Liu WJ; Liu W; Li X; Qin C; Shi Y; Yan J; Zhou D; Gao GF
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
    Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
    Dicks MD; Spencer AJ; Edwards NJ; Wadell G; Bojang K; Gilbert SC; Hill AV; Cottingham MG
    PLoS One; 2012; 7(7):e40385. PubMed ID: 22808149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
    Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
    Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.
    Sridhar S; Reyes-Sandoval A; Draper SJ; Moore AC; Gilbert SC; Gao GP; Wilson JM; Hill AV
    J Virol; 2008 Apr; 82(8):3822-33. PubMed ID: 18256155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
    Front Immunol; 2018; 9():335. PubMed ID: 29563911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
    Ba L; Yi CE; Zhang L; Ho DD; Chen Z
    Appl Microbiol Biotechnol; 2007 Oct; 76(5):1131-6. PubMed ID: 17581748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice.
    Chunling M; Kun Y; Jian X; Jian Q; Hua S; Minsheng Z
    Intervirology; 2006; 49(5):307-18. PubMed ID: 16809936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
    See RH; Petric M; Lawrence DJ; Mok CPY; Rowe T; Zitzow LA; Karunakaran KP; Voss TG; Brunham RC; Gauldie J; Finlay BB; Roper RL
    J Gen Virol; 2008 Sep; 89(Pt 9):2136-2146. PubMed ID: 18753223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.
    Cheng T; Wang X; Song Y; Tang X; Zhang C; Zhang H; Jin X; Zhou D
    Vaccine; 2016 Sep; 34(41):4875-4883. PubMed ID: 27576071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.
    Zakhartchouk AN; Viswanathan S; Mahony JB; Gauldie J; Babiuk LA
    J Gen Virol; 2005 Jan; 86(Pt 1):211-215. PubMed ID: 15604448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
    Cavanagh D
    Avian Pathol; 2003 Dec; 32(6):567-82. PubMed ID: 14676007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
    Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
    J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques.
    Kobinger GP; Figueredo JM; Rowe T; Zhi Y; Gao G; Sanmiguel JC; Bell P; Wivel NA; Zitzow LA; Flieder DB; Hogan RJ; Wilson JM
    Vaccine; 2007 Jul; 25(28):5220-31. PubMed ID: 17559989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
    Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
    J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.